MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows
Business Wire•04/11/2026•08:01 ET
0
Key Highlights
- ➤MindWalk (HYFT) signs multi-year Teva Australia agreement for ReefIQ and LensAI deployment
- ➤ReefIQ and LensAI will support antibody-discovery decisions and design optimization
- ➤Financial terms were not disclosed
- ➤Agreement represents recurring-revenue platform relationship for MindWalk
- ➤MindWalk is discussing additional ReefIQ deployments with life sciences organizations
Expert Statements
Jennifer Bath, President and Chief Executive Officer of MindWalk
“Across the industry, the constraint in antibody discovery is no longer generating data. It is connecting and governing that data and carrying what a program team learns to the next phase. That is exactly what ReefIQ was built to do for companies.”
Anthony Doyle, Vice President, Antibody Discovery at Teva Australia
“The power of AI in drug discovery is not in generating more possibilities, it’s about helping scientists find the ones that matter. By pairing computational insight with deep biological expertise and experimental validation, we can make smarter decisions earlier and focus on antibodies with the greatest potential to become meaningful medicines.”
MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows
Multi-year agreement covers a defined deployment of ReefIQ™ and specified LensAI™ capabilities
Get started
Create a free account to read the full story.